Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 5/20 | 0.33 |
| ▸ | LIMK2 | P53671 | 5/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 2/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13901881 | 0.90 | NPC1 (0.40) | NPC1RAB9AGRM5PKMADORA2A | |
| SCHEMBL4019947 | 0.82 | NPC1 (0.35) | NPC1RAB9AGRM5ACLYADORA2A | |
| SCHEMBL4017715 | 0.82 | GRM5 (0.40) | NPC1RAB9AGRM5PKMACLY | |
| SCHEMBL4021496 | 0.80 | LATS1 (0.38) | NPC1RAB9AGRM5LIMK1LIMK2 | |
| SCHEMBL4022005 | 0.80 | LATS1 (0.38) | NPC1RAB9AGRM5LIMK1LIMK2 | |
| SCHEMBL4021324 | 0.80 | LATS1 (0.38) | NPC1RAB9AGRM5LIMK1LIMK2 | |
| SCHEMBL4022147 | 0.79 | METAP1 (0.51) | NPC1RAB9AGRM5KDM4E | |
| SCHEMBL13901882 | 0.73 | LATS1 (0.38) | NPC1RAB9ALIMK1LIMK2 | |
| SCHEMBL13901884 | 0.72 | DHODH (0.36) | NPC1RAB9AGRM5ADORA2ALIMK1 | |
| SCHEMBL2836367 | 0.72 | ACLY (0.39) | GRM5ACLYCYP11B2P2RX7NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891052-A1 | TUBULIN INHIBITOR AND PROCESS FOR ITS PREPARATION | Wyeth (US) | 2008-02-27 | — | — | EP | claimed |
| US-7244736-B2 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2007-07-17 | — | — | US | claimed |
| WO-2006138180-A1 | TUBULIN INHIBITOR AND PROCESS FOR ITS PREPARATION | WYETH (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060281760-A1 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2006-12-14 | — | — | US | claimed |
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3219207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3219207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-9649317-B2 | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20070249627-A1 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2007-10-25 | — | — | US | disclosed |
| US-7244736-B2 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244736-B2 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2006138180-A1 | TUBULIN INHIBITOR AND PROCESS FOR ITS PREPARATION | WYETH (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060281760-A1 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2006-12-14 | — | — | US | disclosed |
| EP-1663241-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030216-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | WYETH (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, PRNP, PSEN2 | NPC1 619/4885RAB9A 3442/4885GRM5 267/4885 |
| US-20070249627-A1 | Tubulin inhibitor and process for its preparation | TUBB1, TUBB6, TUBB | NPC1 1716/4885RAB9A 2183/4885GRM5 3680/4885 |
| US-20060281760-A1 | Tubulin inhibitor and process for its preparation | TUBB1, TUBB6, TUBB | NPC1 1716/4885RAB9A 2183/4885GRM5 3680/4885 |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | DPYD, ABCC1, ARF5 | NPC1 344/4885RAB9A 1380/4885GRM5 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.